Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Mortimer

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
MGMA Connexion|October 17, 2002
Up, up and away. Malpractice insurance costs continue to soarRichard Mortimer
Nature Reviews. Drug Discovery|January 4, 2011
Data exclusivity for biologicsHenry Grabowski, Genia Long, Richard Mortimer
Seton Hall Law Review|July 12, 2011
Implementation of the biosimilar pathway: economic and policy issuesHenry Grabowski, Genia Long, Richard Mortimer
Journal of Medical Economics|September 16, 2014
Evolving provider payment models and patient access to innovative medical technologyGenia Long, Richard Mortimer, Geoffrey Sanzenbacher
Journal of Medical Economics|December 11, 2013
Recent trends in brand-name and generic drug competitionHenry Grabowski, Genia Long, Richard Mortimer
Journal of Medical Economics|July 13, 2021
Continuing trends in U.S. brand-name and generic drug competitionHenry Grabowski, Genia Long, Richard Mortimer, et al.
Journal of Medical Economics|April 12, 2016
Updated trends in US brand-name and generic drug competitionHenry Grabowski, Genia Long, Richard Mortimer, et al.
Health Affairs (Project Hope)|November 10, 2011
Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman ActHenry G Grabowski, Margaret Kyle, Richard Mortimer, et al.
Health Affairs (Project Hope)|May 9, 2007
Authorized generic drugs, price competition, and consumers' welfareErnst R Berndt, Richard Mortimer, Ashoke Bhattacharjya, et al.
Current Medical Research and Opinion|May 3, 2019
Cardiac arrhythmia detection outcomes among patients monitored with the Zio patch system: a systematic literature reviewMihran Yenikomshian, John Jarvis, Cody Patton, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
MGMA Connexion|October 17, 2002
Up, up and away. Malpractice insurance costs continue to soarRichard Mortimer
Nature Reviews. Drug Discovery|January 4, 2011
Data exclusivity for biologicsHenry Grabowski, Genia Long, Richard Mortimer
Seton Hall Law Review|July 12, 2011
Implementation of the biosimilar pathway: economic and policy issuesHenry Grabowski, Genia Long, Richard Mortimer
Journal of Medical Economics|September 16, 2014
Evolving provider payment models and patient access to innovative medical technologyGenia Long, Richard Mortimer, Geoffrey Sanzenbacher
Journal of Medical Economics|December 11, 2013
Recent trends in brand-name and generic drug competitionHenry Grabowski, Genia Long, Richard Mortimer
Journal of Medical Economics|July 13, 2021
Continuing trends in U.S. brand-name and generic drug competitionHenry Grabowski, Genia Long, Richard Mortimer, et al.
Journal of Medical Economics|April 12, 2016
Updated trends in US brand-name and generic drug competitionHenry Grabowski, Genia Long, Richard Mortimer, et al.
Health Affairs (Project Hope)|November 10, 2011
Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman ActHenry G Grabowski, Margaret Kyle, Richard Mortimer, et al.
Health Affairs (Project Hope)|May 9, 2007
Authorized generic drugs, price competition, and consumers' welfareErnst R Berndt, Richard Mortimer, Ashoke Bhattacharjya, et al.
Current Medical Research and Opinion|May 3, 2019
Cardiac arrhythmia detection outcomes among patients monitored with the Zio patch system: a systematic literature reviewMihran Yenikomshian, John Jarvis, Cody Patton, et al.
Pageof 2